1st Edition

Pharmaceutical Biocatalysis Fundamentals, Enzyme Inhibitors, and Enzymes in Health and Diseases

Edited By Peter Grunwald Copyright 2019
    800 Pages 34 Color & 74 B/W Illustrations
    by Jenny Stanford Publishing

    800 Pages 34 Color & 74 B/W Illustrations
    by Jenny Stanford Publishing

    This book provides an overview of the world market of therapeutic enzymes and enzyme inhibitors, rare diseases, orphan drugs, the costs of drug development and therapies, and enzymes in downstream processing of pharmaceuticals. It discusses carbonic anhydrase inhibitors and their multiple drug interactions, carboxylesterase inhibitors for pharmaceutical applications, employment of inhibitors for the treatment of neurodegenerative diseases, use of engineered proteins, bioactive peptides, and fibrinolytic enzymes for thrombolytic therapy, and enzymes important for the design and development of new drugs/drug metabolites such as aldehyde oxidases and cytochrome P450 enzymes and the role the latter play in vascular biology and pathophysiology. The treatment of cancer is explored in connection with enzymatic amino acid deprivation therapies and new drugs that act as chemical degraders of oncogenic proteins. The book also introduces the resistance mechanisms of cancer. Furthermore, it provides an insight into the relationship between pathological conditions of cardiovascular disease and oxidative stress. The text also focuses on the potential use of nanoparticles as carriers for enzymes with medical relevance, computer-aided drug design for the identification of multi-target directed ligands, and the development of improved therapeutics through a glycan-“designer” approach. It concludes with an introduction to the chemoenzymatic synthesis of drugs.

    Pharmaceuticals: Some General Aspects

    Peter Grunwald

    Use of Enzymes in the Downstream Processing of Biopharmaceuticals

    Duarte Miguel F. T. Prazeres

    Therapeutic Use of Carbonic Anhydrase Inhibitors and Their Multiple Drug Interactions

    Andrea Angeli and Claudiu T. Supuran

    Fibrinolytic Enzymes for Thrombolytic Therapy

    Swaroop S Kumar, Sabu Abdulhameed

    Role of Engineered Proteins as Therapeutic Formulations

    Khushboo Gulati and Krishna Mohan Poluri

    Synthesis of bioactive peptides for pharmaceutical applications

    Jaison Jeevanandam et al.

    Cardiovascular Disease and Oxidative Stress

    Marco Fernandes, Alisha Patel, and Holger Husi

    Enzymatic Amino Acid Deprivation Therapies Targeting Cancer

    Carla S. S. Teixeira et al.

    Carboxylesterase inhibitors: Relevance for Pharmaceutical Applications

    Li-Wei Zou abd Guang-Bo Ge

    Molecular Aspects of the Activity and Inhibition of the FAD-containing Monoamine Oxidases

    Rona R. Ramsay

    Multifunctional Monoamine Oxidase and Cholinesterase Inhibitors for the Treatment of Alzheimer’s Disease

    Ireen Denya, Sarel F. Malan, and Jacques Joubert

    The Neurodegenerative Characteristics of Alzheimer’s Disease and Related Multi-Target Drug Design Studies

    Hayrettin Ozan Gülcan, and Ilkay Erdogan Orhan

    Aldehyde Oxidases as Enzymes in Phase I Drug Metabolism

    Cristiano Mota et al.

    Cytochrome P450 Enzymes for the Synthesis of Novel and Known Drugs and Drug Metabolites

    Sanjana Haque et al.

    Cytochromes P450, Cardiovascular Homeostasis and Disease

    Chin Eng Ong et al.

    Protein Degradation Inducers SNIPERs and PROTACs against Oncogenic Proteins

    Norihito Shibata et al.

    Resistance Mechanisms of Tumor Cells

    Rolf Marschalek

    Biocatalytic Nanoreactors for Medical Purposes

    Oscar González-Davis, Kanchan Chauhan, and Rafael Vazquez-Duhalt

    Computer-Aided Drug Design for the Identification of Multi-Target Directed Ligands (MTDLs) in Complex Diseases: An Overview

    Pravin Ambure and Kunal Roy

    The Development of Improved Therapeutics through a Glycan-‘Designer’ Approach

    Natalia G. Bednarska

    On Biocatalysis as Resourceful Methodology for Complex Syntheses: Selective Catalysis, Cascades, and Biosynthesis

    Andreas Sebastian Klein, Thomas Classen, and Jörg Pietruszka


    Peter Grunwald studied chemistry at the Universities of Saarbrücken and Hamburg, Germany. He graduated in the field of high-frequency spectroscopy and then became a staff member of the Institute of Physical Chemistry. After receiving his PhD in physical chemistry, he founded a biotechnology research group. He was appointed professor in 2001. His research interests focus on immobilized biocatalysts, kinetics of enzymes in organic solvents, and interactions between biocatalysts and heavy metal ions. Prof. Grunwald is also interested in chemical education, including curriculum development. He has authored a textbook on biochemistry and is an editorial board member of Catalysts.

    “This book is an important addition to the literature in this field. It not only summarizes the importance of enzymes as targets for pharmaceutical drug research in the past but also shows that there is still enormous potential in the future. Motivated by Peter Grunwald, a large group of experts have shared their specialist knowledge. The book a treasure for anyone working or doing research in the field.”
    Prof. Theo Dingermann, Goethe University, Germany
    “This book represents an outstanding scientific work. It covers the state of the art, challenges, and key achievements of research focusing on the use of enzymes for therapeutic purposes. It discusses the fundamentals of enzyme function and its applications and shows how this fantastic research field has been explored in drug discovery and innovation for gaining a better understanding of enzymes and their use for a better quality of life.”
    Prof. Cláudio Viegas Jr., Universidade Federal de Alfenas, Brazil